Literature DB >> 22592843

Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.

Jihane Abou Rahal, Rim S Ishak, Zaher K Otrock, Abdul-Ghani Kibbi, Ali T Taher.   

Abstract

Livedoid vasculopathy is characterized by painful purpuric lesions on the extremities which frequently ulcerate and heal with atrophic scarring. For many years, livedoid vasculopathy has been considered to be a primary vasculitic process. However, there has been evidence considering livedoid vasculopathy as an occlusive vasculopathy due to a hypercoagulable state. We present the case of livedoid vasculopathy in a 21-year-old female who had been suffering of painful lower extremity lesions of 3 years duration. The patient was found to be lupus anticoagulant positive and homozygous for methylenetetrahydrofolate reductase C677T mutation. The patient was successfully treated with low-molecular-weight heparin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592843     DOI: 10.1007/s11239-012-0743-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  11 in total

Review 1.  Atrophie blanche.

Authors:  M B Maessen-Visch
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2000-05       Impact factor: 2.435

2.  Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.

Authors:  Bethany R Hairston; Mark D P Davis; Lawrence E Gibson; Lisa A Drage
Journal:  Arch Dermatol       Date:  2003-08

3.  Difficult management of livedoid vasculopathy.

Authors:  Camille Francès; Stéphane Barete
Journal:  Arch Dermatol       Date:  2004-08

4.  Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin.

Authors:  Tobias Goerge; Carsten Weishaupt; Dieter Metze; Ulrike Nowak-Göttl; Cord Sunderkötter; Martin Steinhoff; Stefan W Schneider
Journal:  Arch Dermatol       Date:  2010-08

Review 5.  Livedoid vasculopathy as a coagulation disorder.

Authors:  Paulo Ricardo Criado; Evandro Ararigboia Rivitti; Mirian Nacagami Sotto; Jozélio Freire de Carvalho
Journal:  Autoimmun Rev       Date:  2010-12-22       Impact factor: 9.754

6.  Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs--a prospective study.

Authors:  T B Di Giacomo; T P Hussein; D G Souza; P R Criado
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-11       Impact factor: 6.166

7.  Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease.

Authors:  Elizabeth A Varga; Amy C Sturm; Caron P Misita; Stephan Moll
Journal:  Circulation       Date:  2005-05-17       Impact factor: 29.690

Review 8.  Livedoid vasculopathy: thrombotic or inflammatory disease?

Authors:  S Khenifer; L Thomas; B Balme; S Dalle
Journal:  Clin Exp Dermatol       Date:  2010-10       Impact factor: 3.470

9.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

10.  Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome.

Authors:  Raquel Cardoso; Margarida Gonçalo; Oscar Tellechea; Rosa Maia; Catarina Borges; J A Pereira Silva; Américo Figueiredo
Journal:  Int J Dermatol       Date:  2007-04       Impact factor: 2.736

View more
  1 in total

Review 1.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.